Biotech and Pharma Stocks: High Volume Traders; (OTCBB: UVFT), (NASDAQ:AMGN), (OTCBB: GNTA), (NASDAQ:BCRX)
Point Roberts, WA – December 15, 2010 (Investorideas.com Newswire) - InvestorIdeas.com, a leader in sector research for investors including biotech and pharma stocks , reports on recent Volume Leading Biotech/ Pharma Stocks news and trading for December 15th for NASDAQ and microcap stocks.
Biotech Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc., (OTCBB: UVFT), trading at $ 0.1090, up 0.0090 (9.00%) on over 1.5 Million shares in Volume
Amgen Inc. (NASDAQ: AMGN) trading at $56.20
Genta Inc. (OTCBB: GNTA), trading at $0.0497, up 0.0181 (57.28%) on over 22 Million Shares in Volume
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) trading at $5.23, up 0.10 (1.75%)
Biotech Stocks News and Profiles-
UV Flu Technologies, Inc., (OTCBB: UVFT) Recent News:
UV Flu Technologies (OTCBB: UVFT) to Finalize Acquisition of Leading Industrial Grade Air Purification Manufacturer
“CENTERVILLE, MA – December 15, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), is pleased to announce that it is moving
forward with plans to acquire a renowned US manufacturer of high quality air purification equipment designed for industrial applications including specialization in the medical and hospitality marketplace.
The final milestone prior to the close of the agreement was the completion of a financial audit, which was successfully concluded last week. A tentative closing date has been targeted for on or around December 30, 2010.
The agreement includes a patented, trademarked product line, with dozens of national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The company's sales include an installed base of several thousand units in over 1000 unique facilities nationwide, including over 400 hospitals.”
Full Article: http://www.investorideas.com/CO/UVFT/news/12151.asp
Genta Inc. (OTCBB: GNTA) Recent News:
Genta Completes $5 Million Financing
“BERKELEY HEIGHTS, N.J, Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors that released $5 million in gross proceeds from a control account that had been established pursuant to the issuance of
Convertible Notes in March 2010. The funds had been subject to certain restrictions and security interests, which have been released with the new agreements.
Proceeds of this transaction will be used as follows:
to determine survival results from Genta's completed Phase 3 trial of Genasense® (oblimersen sodium) Injection plus chemotherapy as first-line treatment of patients with advanced melanoma (known as AGENDA). Followup from AGENDA will complete in the 1st-quarter 2011;
to complete Phase 2 and initiate a Phase 3 trial with tesetaxel, the leading oral taxane in clinical
to select a lead oral gallium-containing compound that will advance to clinical trials for treatment of diseases associated bone loss.”
Full News at: http://finance.yahoo.com/news/Genta-Completes-5-Million-bw-244255153.htm...
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) Recent News:
BioCryst Reports New Data from Its Phase 2 Forodesine Study in Patients with Chronic Lymphocytic Leukemia at the 52nd Annual American Society of Hematology Meeting
“RESEARCH TRIANGLE PARK, N.C,BioCryst Pharmaceuticals, Inc. today announced the presentation of new data that confirms forodesine's clinical activity in the treatment of chronic lymphocytic leukemia (CLL) at the 52nd Annual American Society of Hematology (ASH) Meeting & Exposition being held in Orlando, Florida.
In this Phase 2, open-label, single-arm, multi-center study, forodesine was administered orally at 200 mg twice-daily for 28-day cycles in previously treated CLL patients. The primary endpoint of the study was overall response rate. An analysis conducted after all patients were followed through ≥6 months showed that six of 23 response-evaluable patients demonstrated a partial
response to forodesine, resulting in a response rate of 26 percent. Forodesine 200 mg orally-administered twice-daily was generally safe and well-tolerated in this study. The pattern, frequencies and severity distribution of adverse events were generally consistent with CLL-associated poor bone marrow function and immunodeficiency, prior therapies and co-morbidities.”
Full News at: http://finance.yahoo.com/news/BioCryst-Reports-New-Data-bw-3582084115.ht...
Amgen Inc. (NASDAQ: AMGN) Recent News:
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Pivotal Phase 3 '147 Study Meets Primary Endpoint
First Bone-Targeted Therapy to Delay the Onset of Bone Metastases in Patients with Prostate Cancer
“THOUSAND OAKS, Calif., Dec. 13, 3010 Amgen today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-
0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first occurrence of bone metastases (secondary endpoint). Overall survival was similar between the XGEVA and placebo groups (secondary endpoint).
Overall rates of adverse events and serious adverse events were generally similar between XGEVA and placebo, with hypocalcemia and osteonecrosis of the jaw (ONJ) observed at increased frequencies in the XGEVA arm. The yearly rate of ONJ in the XGEVA-treated group was similar to what has been observed in prior XGEVA trials.”
Full News at: http://finance.yahoo.com/news/XGEVA-Denosumab-Significantly-prnews-25157...
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, covering leading industry sectors including mining and gold stocks, in addition to global markets
including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive
stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/
About our Biotech investor portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector,
within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio,
research reports and our stock directories.
Showcase Biotech Stock UV Flu Technologies, Inc. (UVFT.OB):
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration
to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available Visit the showcase page on Investorideas.com For UV Flu Technologies, Inc., (OTCBB:UVFT)
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Geaux IR Services, Inc.
SOURCE: UV Flu Technologies, Inc.
Get added to the company's news alerts:
Disclaimer: Disclaimer: The following news/content is paid for as part of the UVFT showcase program (two thousand
per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
.Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - email@example.com
Source - Investorideas.com
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.